Renalytix AI PLC US Exec Order on Advancing American Kidney Health
July 12 2019 - 1:00AM
RNS Non-Regulatory
TIDMRENX
Renalytix AI PLC
12 July 2019
Renalytix AI plc
("RenalytixAI" or the "Company")
US Executive Order on Advancing American Kidney Health
Renalytix AI welcomes US Administration's dedication to
advancing American kidney health
Renalytix AI plc (AIM: RENX), a developer of artificial
intelligence enabled clinical diagnostics for kidney disease,
welcomes the Executive Order signed by the President of the United
States of America on 10 July 2019 to launch Advancing American
Kidney Health, a new initiative to improve the lives of Americans
suffering from kidney disease, expand options for American
patients, and reduce healthcare costs.
The Executive Order sets out the policy of the United States to
prevent kidney failure whenever possible through better diagnosis,
treatment and incentives for preventative care. The Secretary of
Health and Human Services (the "Secretary") is expected to launch
an awareness initiative to educate patients and support programmes
that promote kidney disease awareness. In addition, the Secretary
will select a payment model to identify and treat at-risk
populations earlier in disease development. The model should
broaden the range of care and Medicare payment options available to
potential participants with a focus on delaying or preventing the
onset of kidney failure, preventing unnecessary hospitalisations,
and increasing the rate of transplants.
RenalytixAI's lead product, KidneyIntelX(TM), is being developed
to improve the identification and clinical management of patients
with Type 2 diabetes with fast-progressing kidney disease.
KidneyIntelX(TM) uses a machine learning algorithm to assess a
combination of predictive blood-based biomarkers and features from
a patient's electronic health record. In May 2019, KidneyIntelX(TM)
was granted Breakthrough Device designation by the U.S. Food and
Drug Administration (FDA) and on 1 July 2019 the American Medical
Association (AMA) has granted a CPT(R) Proprietary Laboratory
Analyses (PLA) Code for KidneyIntelX(TM). The new code, 0105U, is
scheduled to become effective on 1 October 2019.
In setting out the purpose of the Executive Order, it says:
The state of care for patients with chronic kidney disease and
end-stage renal disease (ESRD) is unacceptable: too many at-risk
patients progress to late-stage kidney failure; the mortality rate
is too high; current treatment options are expensive and do not
produce an acceptable quality of life; and there are not enough
kidneys donated to meet the current demand for transplants.
Kidney disease was the ninth-leading cause of death in the
United States in 2017. Approximately 37 million Americans have
chronic kidney disease and more than 726,000 have ESRD. More than
100,000 Americans begin dialysis each year to treat ESRD. Twenty
percent die within a year; fifty percent die within 5 years.
Currently, nearly 100,000 Americans are on the waiting list to
receive a kidney transplant.
The full text of the Executive Order can be read here:
https://www.whitehouse.gov/presidential-actions/executive-order-advancing-american-kidney-health/
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker) Tel: 020 7710 7600
Alex Price / Jonathan Senior / Ben Maddison
(Investment Banking)
Peter Lees (Corporate Broking)
N+1 Singer (Joint Broker) Tel: 020 7496 3000
Aubrey Powell / James White / George Tzimas (Corporate Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391
303
About Kidney Disease
Kidney disease is now recognised as a public health epidemic
affecting over 850 million people globally. In the United States
alone, over 40 million people are classified as having chronic
kidney disease, with nearly 50 percent of individuals with advanced
(Stage IV) disease unaware of the severity of their reduced kidney
function. As a result, many patients progress to kidney failure in
an unplanned manner, ending up having dialysis in the emergency
room without ever seeing a clinical specialist, such as a
nephrologist. Every day 13 patients die in the United States while
waiting for a kidney transplant.
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled
clinical diagnostic solutions for kidney disease, one of the most
common and costly chronic medical conditions globally. The
Company's solutions are being designed to make significant
improvements in kidney disease diagnosis and prognosis, clinical
care, patient stratification for drug clinical trials, and drug
target discovery. For more information, visit renalytixai.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKFLFFKDFBBBX
(END) Dow Jones Newswires
July 12, 2019 02:00 ET (06:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024